LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, DECEMBER 2, 2026 OR ANY ADJOURNMENT THEREOF

I/We _____ of

(address) _____

being the registered holder(s) of _____
H Share(s)[(Note 2)] with a nominal value of RMB1.00 each in the share capital of **LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*** (the "**Company**"), hereby appoint **the Chairman of the Meeting** or[(Note 3)] _____

of (address) _____
as my/our proxy(ies) to attend and act for me/us at the Extraordinary General Meeting (the "**EGM**") to be held at 10:30 a.m. on Wednesday, December 2, 2026 at Conference Room, 5th Floor, Building 41, No. 258 Xinzhuan Highway, Songjiang District, Shanghai, the PRC or at any adjournment thereof to vote in respect of the resolutions set out in the notice of the Meeting as hereunder indicated on behalf of me/us, or if no such indication is given, as my/our proxy(ies) think(s) fit. Terms used in this proxy form shall have the same meanings as defined in the circular of the Company dated November 12, 2026 (the "**Circular**").

	ORDINARY RESOLUTIONS	For	Against	Abstain
1.	(a) To consider, approve, and ratify the share transfer agreement (the "**Share Transfer Agreement**") dated August 21, 2026 entered into between the Company, Lepu Medical Technology (Beijing) Co., Ltd. (樂普(北京)醫療器械股份有限公司), and Shanghai Minwei Biotechnology Co., Ltd. (上海民為生物技術有限公司), and the transactions contemplated thereunder (details of which are set out in the Circular); (b) To consider and authorize any one director of the Company on behalf of the Company to do all such acts and sign, execute, seal (where required) and deliver the Share Transfer Agreement and all such other documents and to take all such steps as the directors of the Company in their discretion may consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Share Transfer Agreement and the transactions contemplated thereunder;			
2.	To consider, approve and ratify, conditional upon the ordinary resolution number 1 being approved, the Proposed Change in UOP (details of which are set out in the Circular).			

Further details of the above resolutions are set out in the Circular of the Company.

Date: _____ 2026 Signature(s)[(Note 5)]: _____

Notes:

1. Please insert full name(s) (Chinese or English) and address(es) in **BLOCK CAPITALS** (as shown in the register of members of the Company).
2. Please insert the number of Shares of the Company registered in your name(s) relating to this proxy form and delete as appropriate. If the number is inserted, this form of proxy will be deemed to relate only to those Shares. If the number is not inserted, the form of proxy will be deemed to relate to all Shares of the Company registered in your name(s) (whether alone or jointly with others).
3. If any proxy other than the chairman of the Meeting is preferred, please strike out "**the Chairman of the Meeting** or" and insert the name(s) and address(es) of the proxy(ies) desired in the space provided. A Shareholder may appoint one or more proxies to attend and vote at the Meeting in his/her/its stead. A proxy need not be a Shareholder of the Company but shall attend the Meeting on your behalf in person. Such proxies may only exercise their voting rights in a poll. Any alteration made to this proxy form must be signed by the person who signs it.
4. **IMPORTANT: If you wish to vote in favor of any resolution, please tick the box marked "FOR". If you wish to vote against any resolution, please tick the box marked "AGAINST". If you wish to abstain from voting in respect of any resolution, please tick the box marked "ABSTAIN".** In the absence of such indication, the proxy will be entitled to cast his/her votes at his/her discretion. Your proxy will also be entitled to vote or abstain at his/her discretion in respect of any resolution properly put to the Meeting other than those referred to in the notice of the Meeting. The "ABSTAIN" votes will be counted in the calculation of the required majority.
5. This proxy form shall be signed by you or your attorney duly authorized in writing or, in the case of a legal person, must be either executed under its common seal or under the hand of its legal representative(s), director(s) or duly authorized attorney(s). If that document is signed by an attorney of the Shareholder, the power of attorney authorizing that attorney to sign or other authorization documents shall be notarized.
6. In the case of joint Shareholders, any of such joint Shareholders may vote at the Meeting, either in person or by proxy, in respect of such Shares as if he/she is solely entitled thereto. However, if more than one of such joint Shareholders are present at the Meeting, in person or by proxy, the vote of the joint Shareholder whose name stands first in the register of members of the Company, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s).
7. To be valid, this proxy form together with the notarized power of attorney (if any) or other authorisation document (if any) or a notarially certified copy thereof, must be delivered to the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the time fixed for holding the Meeting or any adjournment thereof.
8. Completion and return of a proxy form will not preclude you from attending and voting in person at the Meeting or any adjournment thereof if he/she so wishes. In such event, the instrument appointing a proxy shall be deemed to be revoked. Shareholders or their proxies attending the Meeting (and any adjournment thereof) shall produce their identity documents.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*